Overview
- The two companies announced a strategic combination that was announced June 17, 2026 and will create a parent called Healthcare Revolution Partners while keeping Abarca and LucyRx as separate, wholly owned brands with current CEOs remaining in place.
- The combined business will serve more than 9 million members and is expected to rank among the top 10 PBMs by prescriptions managed but will remain much smaller than the three largest PBMs that together control roughly 80% of the U.S. market.
- Executives said the deal foregrounds technology and clinical capabilities as its core assets, citing Abarca’s Darwin Healthcare Intelligence platform and LucyRx’s LucyIQ and Connected Specialty Care Network to improve care coordination and pricing transparency.
- The transaction is subject to regulatory approvals and customary closing conditions, has no disclosed financial terms, and the companies expect to close the deal in the third quarter of 2026.
- The move reflects growing pressure on the PBM sector from rising specialty drug costs and new rules on transparency, and it could accelerate further consolidation while reshaping options for employers, government plans, and patients who seek lower drug costs and clearer pricing.